Home › Trials › NCT07414277
Clinical trial Recruiting at 4 sites Interventional Ages 18 to 80

Real-Time Glucose Monitoring After Hospital Discharge in Insulin-Treated Type 2 Diabetes

Official title: Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial

Run by Shanghai 6th People's Hospital · NCT07414277 · Data updated 2026-11-12

This study tests whether real-time continuous glucose monitoring helps people with insulin-treated type 2 diabetes manage blood sugar better after leaving the hospital compared with standard finger-prick glucose checks.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment160 (estimated)
SponsorShanghai 6th People's Hospital
Academic / other
Locations4 sites (Shanghai and 3 other locations)
StatusRecruiting
StartedMay 11, 2026
Main results expectedSeptember 30, 2027
Study endsDecember 31, 2027
Registry record updatedJune 24, 2026
Trial IDNCT07414277 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with type 2 diabetes, HbA1c 8.0–13.0%, and plans to start or continue insulin therapy after hospital discharge.

Probably not a fit

Patients with recent RT-CGM use, pregnancy, severe skin conditions at sensor sites, or those not planning post-discharge insulin therapy may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter randomized trial compares Real-Time Continuous Glucose Monitoring (RT-CGM) to Self-Monitoring of Blood Glucose (SMBG) during a 12-week post-discharge transition in adults with insulin-treated type 2 diabetes. Eighty participants will wear RT-CGM intermittently every 4 weeks, while eighty will perform SMBG, with follow-up visits at Week 12 and Week 24. The trial aims to determine whether RT-CGM improves glycemic control and adherence during this vulnerable transition period. Enrollment targets adults 18-80 with HbA1c 8.0–13.0% and planned post-discharge insulin therapy for at least 6 months. Key exclusion criteria include recent RT-CGM use, active pregnancy, major liver disease, and participation in other trials.

Why it matters

Potential benefit: If successful, RT-CGM could lead to better blood sugar control and fewer discharge-related glycemic complications after leaving the hospital.

How similar studies have gone: Some prior studies suggest RT-CGM can improve glycemic metrics in insulin-treated diabetes, but this transition-focused, post-discharge trial adds new evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age 18 to 80 years (inclusive).
2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM).
3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment.
4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician).

Exclusion Criteria:

1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.
2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives.
3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.
4. Currently participating in, or planning to participate in, another clinical trial.
5. Current use of oral corticosteroid therapy, or anticipated use during the trial period.
6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN).
7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m².
8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.

Where it's running

  • Shanghai 7th People's Hospital
    Shanghai, China     Recruiting
  • Shanghai 6th People's Hospital
    Shanghai, China     Recruiting
  • Shanghai Fengxian District Central Hospital
    Shanghai, China     Recruiting
  • Shanghai General Hospital
    Shanghai, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 2 Diabetes Mellitus (T2DM) 68Shanghai 6th People's Hospital 33
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.